Circadian regulation of MGMT expression and promoter methylation underlies daily rhythms in TMZ sensitivity in glioblastoma
M. F. Gonzalez-Aponte, A. R. Damato, L. L. Trebucq, T. Simon, S. P. Cardenas-Garcia, K. Cho, G. J. Patti, D. A. Golombek, J. J. Chiesa, E. D. Herzog
This study shows that TMZ efficacy in glioblastoma varies with time-of-day due to circadian rhythms in MGMT expression and promoter methylation, with optimal treatment at the peak of Bmal1 expression.
bioRxiv · Sep 13, 2023 · PreprintCancer Biology